Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
about
The mTOR signalling pathway in human cancerNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyTargeting the mTOR signaling network for cancer therapyThe fate of chemoresistance in triple negative breast cancer (TNBC)The role of peroxiredoxin II in chemoresistance of breast cancer cellsPTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationMetabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice.A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Roles of differential expression of microRNA-21-3p and microRNA-433 in FSH regulation in rat anterior pituitary cells.MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression.Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Functional analysis of the protein phosphatase activity of PTENThe Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducibleManagement options in triple-negative breast cancerPhosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyCooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Potential Therapeutic Targets in Uterine Sarcomas.Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice.SLUG is a direct transcriptional repressor of PTEN tumor suppressor.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).Phase II trial of temsirolimus in patients with metastatic breast cancer.Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.Effects of ectopic expression of NGAL on doxorubicin sensitivity.Molecular targets of breast cancer: AKTing in concertDominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyDoxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP MiceDisulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.Impact of genetic alterations on mTOR-targeted cancer therapy
P2860
Q24627306-7B46FE96-653E-425D-9C8E-839E6C96E0C8Q24628724-650A1D07-577F-4A51-8CD3-98C0D9DA277AQ24658334-95F5B5B6-889A-4FC2-99ED-D438F32AB592Q26775232-2D8A5593-379F-4369-BAC3-36765D5930BFQ26824860-1049F500-35EC-49D2-97C8-322A170630D6Q27852528-CE772E4C-C7E0-44F6-8B98-798BD03E62FAQ30390384-7AB6C7E2-72E3-4F2C-9DB5-ED76B777F36BQ33407185-4A8C482B-1253-458E-B4C6-6ADDB2A5C53BQ33823577-D051E391-2865-4309-880D-E4A743251B72Q33829561-DAEEB935-5066-47DF-99CE-0C47A8416520Q33917538-FBB33236-C50C-45E1-95E1-4F65F60E1D96Q33917551-2FB41D75-7912-41D7-A86C-28883C7A8BE4Q33990018-1EF25FE4-DCA0-49C9-AFCC-388173095594Q34062367-BDC54D0E-2596-4987-87D0-FAD715E720DFQ34103963-16C2C342-9823-4B69-96A4-AC460B3FD20EQ34173253-EE20155A-19BA-4075-B07E-C1E5E6BE6EF7Q34194118-51556316-454A-4732-ADB6-418E7A835D7EQ34309903-FAB595C5-043C-4E04-ACD3-740AFC4A602EQ34574472-F03180EB-E49D-46CF-BB98-92C4B6397837Q35155460-F7CDB61E-4868-44D2-BDC0-D8DE488242F0Q35235757-44DC37A7-FB0B-4514-BCAE-EBED17C048AEQ35556981-2A9B1FD4-ECCE-4A04-B0A4-571E8104053CQ35584560-8265AD62-7540-46F8-90BF-BC7C8B9D8D53Q35640228-F06F0C86-2B36-444C-8A40-955F574064B4Q35640301-79BBD7DF-DF96-419D-BE05-C02643A0F2AEQ36245677-687244C2-88DE-449F-912D-1765DC3A815FQ36277846-86D5A377-B71A-4832-92D6-2B112D1248D8Q36303130-DAA6DE96-B029-4E9D-8EF7-DEDA5669E9A9Q36318871-4564FC6E-C901-4FE1-8B42-D69CDD0EDAE7Q36640056-69DD9125-0FD8-4E3C-8E56-B054D46C5CD8Q36856121-9F17C5B9-61FF-4D83-BF4A-70C9B12A1957Q36963025-F6006854-F846-40CA-9780-8E5357C2483FQ37031268-6F2F45F0-06CF-4BB5-93C0-616CB55EDFF4Q37183674-1FA616D9-8B20-4839-83DB-647060F3630BQ37192602-E303CBF3-D8CC-4803-BC1A-26169523B423Q37192611-0DA9AE5C-CD1C-4AEE-98D6-2E84C3559039Q37192616-5FB4B7C8-E7A1-4F22-A7BC-75845AD4D189Q37219900-17846D83-C09D-4BA2-9A86-4A291006975FQ37307459-470CD551-C39B-47EB-8E7B-E5D153C52FA1Q37353954-E77D40A8-92BB-4EEB-9CDC-F998A8B71314
P2860
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@en
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@nl
type
label
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@en
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@nl
prefLabel
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@en
Suppression of PTEN function i ...... ensitivity to mTOR inhibitors.
@nl
P2093
P2860
P50
P356
P1433
P1476
Suppression of PTEN function i ...... sensitivity to mTOR inhibitors
@en
P2093
A M Martelli
D M Terrian
E W T Wong
J R Taylor
K M Stadelman
L S Steelman
M L Sokolosky
P M Navolanic
S L Abrams
P2860
P2888
P304
P356
10.1038/ONC.2008.49
P407
P577
2008-03-10T00:00:00Z